p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA

Aberrant p62 overexpression has been implicated in breast cancer development. Here, we found that p62 expression was elevated in breast cancer stem cells (BCSCs), including CD44+CD24− fractions, mammospheres, ALDH1+ populations and side population cells. Indeed, short-hairpin RNA (shRNA)-mediated knockdown of p62 impaired breast cancer cells from self-renewing under anchorage-independent conditions, whereas ectopic overexpression of p62 enhanced the self-renewal ability of breast cancer cells in vitro. Genetic depletion of p62 robustly inhibited tumor-initiating frequencies, as well as growth rates of BCSC-derived tumor xenografts in immunodeficient mice. Consistently, immunohistochemical analysis of clinical breast tumor tissues showed that high p62 expression levels were linked to poorer clinical outcome. Further gene expression profiling analysis revealed that p62 was positively correlated with MYC expression level, which mediated the function of p62 in promoting breast cancer stem-like properties. MYC mRNA level was reduced upon p62 deletion by siRNA and increased with p62 overexpression in breast cancer cells, suggesting that p62 positively regulated MYC mRNA. Interestingly, p62 did not transactivate MYC promoter. Instead, p62 delayed the degradation of MYC mRNA by repressing the expression of let-7a and let-7b, thus promoting MYC mRNA stabilization at the post-transcriptional level. Consistently, let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization. Together, these findings unveiled a previously unappreciated role of p62 in the regulation of BCSCs, assigning p62 as a promising therapeutic target for breast cancer treatments.

[1]  N. Betz,et al.  The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. , 1998, Nucleic acids research.

[2]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[3]  T. Golub,et al.  Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.

[4]  H. Cai,et al.  Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. , 2015, Oncology reports.

[5]  Harikrishna Nakshatri,et al.  SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype , 2010, BMC Cancer.

[6]  A. McEvoy,et al.  The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells , 2013, Oncogene.

[7]  D. Simeone,et al.  Identification of human pancreatic cancer stem cells. , 2009, Methods in molecular biology.

[8]  Alison Jones,et al.  Educating undergraduate medical students about oncology: a literature review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[10]  S. Srikantan,et al.  HuR recruits let-7/RISC to repress c-Myc expression. , 2009, Genes & development.

[11]  D. Kwiatkowski,et al.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent , 2011, Proceedings of the National Academy of Sciences.

[12]  U. Dafni,et al.  CRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expression. , 2003, Anticancer research.

[13]  A. Nigam.  Breast Cancer Stem Cells, Pathways and Therapeutic Perspectives 2011 , 2013, Indian Journal of Surgery.

[14]  B. Wold,et al.  p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells , 2003, Oncogene.

[15]  H. Kubo,et al.  Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma , 2012, Cancer science.

[16]  M. Diaz-Meco,et al.  The atypical protein kinase Cs , 2000, EMBO reports.

[17]  Erez Y. Levanon,et al.  m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation , 2015, Science.

[18]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[19]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[20]  E. Wahle,et al.  Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. , 2008, RNA.

[21]  Ramars Amanchy,et al.  Phosphorylation of p62 by cdk1 Controls the Timely Transit of Cells through Mitosis and Tumor Cell Proliferation , 2010, Molecular and Cellular Biology.

[22]  I. Lafon,et al.  Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins , 1998, Oncogene.

[23]  Feimeng Zheng,et al.  A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor–Initiating Cells and Overcomes Drug Resistance , 2014, Molecular Cancer Therapeutics.

[24]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[25]  Q. Sun,et al.  CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma , 2012, Journal of experimental & clinical cancer research : CR.

[26]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[27]  M. Řezáčová,et al.  Breast Cancer and Cancer Stem Cells: A Mini-Review , 2014, Tumori.

[28]  E. Lam,et al.  OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance , 2015, Oncogene.

[29]  H. Kung,et al.  MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[30]  Aleksey A. Porollo,et al.  p62 is a key regulator of nutrient sensing in the mTORC1 pathway. , 2011, Molecular cell.

[31]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[32]  T. Mizushima,et al.  Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. , 2013, Molecular cell.

[33]  J. Strominger,et al.  p62, a Phosphotyrosine-independent Ligand of the SH2 Domain of p56lck, Belongs to a New Class of Ubiquitin-binding Proteins* , 1996, The Journal of Biological Chemistry.

[34]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[35]  G. Bjørkøy,et al.  p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy* , 2007, Journal of Biological Chemistry.

[36]  C. Sander,et al.  SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. , 2013, Cancer cell.

[37]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[38]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Cui,et al.  p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. , 2014, International journal of oncology.

[40]  J. Flores,et al.  The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.

[41]  E. Schmidt,et al.  Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway , 2009, Cell cycle.

[42]  I. Lemm,et al.  Regulation of c-myc mRNA Decay by Translational Pausing in a Coding Region Instability Determinant , 2002, Molecular and Cellular Biology.

[43]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[44]  S. Tsao,et al.  © The Author(s) 2010. This article is published with open access at Springerlink.com , 2010 .

[45]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Patricia Soteropoulos,et al.  MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. , 2007, Cancer research.

[47]  Jia Fu,et al.  Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer , 2013, OncoTargets and therapy.

[48]  Keiji Tanaka,et al.  Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells , 2011, The Journal of cell biology.

[49]  Jie Fan,et al.  Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. , 2012, Biochemical and biophysical research communications.

[50]  A. Thorburn,et al.  Regulation of cell proliferation and migration by p62 through stabilization of Twist1 , 2014, Proceedings of the National Academy of Sciences.

[51]  Frank Pajonk,et al.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.

[52]  F. Peng,et al.  Aurora kinase A suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells , 2014, OncoTarget.

[53]  L. Allen.  Stem cells. , 2003, The New England journal of medicine.

[54]  I. Ellis,et al.  The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. , 2007, Endocrine-related cancer.

[55]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[56]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[57]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[59]  Ruiying Zhao,et al.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[60]  Jie Xu,et al.  Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast Cancer , 2013, PloS one.

[61]  N. Sato,et al.  Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue , 2006, Histopathology.

[62]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[63]  J. Menéndez,et al.  Autophagy in stem cells , 2013, Autophagy.